Equities research analysts predict that Exelixis, Inc. (NASDAQ:EXEL) will announce sales of $195.72 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Exelixis’ earnings, with estimates ranging from $172.30 million to $220.09 million. Exelixis posted sales of $120.07 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 63%. The business is scheduled to issue its next quarterly earnings results after the market closes on Tuesday, February 12th.

On average, analysts expect that Exelixis will report full-year sales of $819.43 million for the current financial year, with estimates ranging from $796.20 million to $845.31 million. For the next year, analysts forecast that the business will report sales of $919.04 million, with estimates ranging from $849.80 million to $1.00 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Exelixis.

EXEL has been the topic of a number of analyst reports. ValuEngine downgraded shares of Exelixis from a “hold” rating to a “sell” rating in a report on Saturday, January 19th. BidaskClub downgraded shares of Exelixis from a “buy” rating to a “hold” rating in a report on Saturday, January 19th. Piper Jaffray Companies lowered their target price on Exelixis from $29.00 to $26.00 and set an “overweight” rating on the stock in a research note on Monday, November 5th. Oppenheimer set a $40.00 target price on Exelixis and gave the stock a “buy” rating in a research note on Thursday, November 15th. Finally, TheStreet upgraded Exelixis from a “c+” rating to a “b-” rating in a research note on Monday, December 17th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $28.38.

In related news, Director George A. Scangos sold 40,000 shares of the business’s stock in a transaction dated Friday, February 1st. The stock was sold at an average price of $23.53, for a total value of $941,200.00. Following the sale, the director now directly owns 1,363,031 shares in the company, valued at approximately $32,072,119.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Patrick J. Haley sold 1,560 shares of the business’s stock in a transaction dated Wednesday, January 9th. The shares were sold at an average price of $23.50, for a total value of $36,660.00. The disclosure for this sale can be found here. Insiders have sold a total of 361,807 shares of company stock worth $7,657,432 over the last quarter. Company insiders own 4.80% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. ETRADE Capital Management LLC bought a new stake in Exelixis in the 4th quarter valued at about $306,000. Costello Asset Management INC bought a new stake in Exelixis in the 4th quarter valued at about $211,000. BlackRock Inc. raised its stake in Exelixis by 1.6% in the 4th quarter. BlackRock Inc. now owns 30,584,751 shares of the biotechnology company’s stock valued at $601,600,000 after acquiring an additional 490,747 shares during the period. Campbell & CO Investment Adviser LLC bought a new stake in Exelixis in the 4th quarter valued at about $403,000. Finally, New York State Common Retirement Fund raised its stake in Exelixis by 105.3% in the 4th quarter. New York State Common Retirement Fund now owns 1,188,940 shares of the biotechnology company’s stock valued at $23,386,000 after acquiring an additional 609,740 shares during the period. Institutional investors and hedge funds own 77.63% of the company’s stock.

EXEL opened at $21.27 on Friday. The company has a current ratio of 8.66, a quick ratio of 8.54 and a debt-to-equity ratio of 0.01. The firm has a market cap of $6.34 billion, a price-to-earnings ratio of 41.71, a PEG ratio of 1.41 and a beta of 2.21. Exelixis has a 1 year low of $13.42 and a 1 year high of $30.24.

About Exelixis

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Read More: What is a Futures Contract?

Get a free copy of the Zacks research report on Exelixis (EXEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.